Do you want to read an article? Please log in or register.
Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
Rheumatoid Arthritis
Related content
Rheumatoid Arthritis
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).
Ann Rheum Dis.
Smolen JS, Kremer JM, Gaich CL, DeLozier AM, Schlichting DE, Xie L, Stoykov I, Rooney T, Bird P, Sánchez Bursón JM, Genovese MC, Combe B
doi: 10.1136/
Rheumatoid Arthritis
Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
RMD Open.
Emery P, Blanco R, Maldonado Cocco J, Chen YC, Gaich CL, DeLozier AM, de Bono S, Liu J, Rooney T, Chang CH, Dougados M
doi: 10.1136/rmdopen-2016-000410.
Rheumatoid Arthritis
Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry
Rheumatol Ther.
Pappas DA, Kremer JM, Griffith J, Reed G, Salim B, Karki C, Garg V
doi: 10.1007/s40744-017-0077-z.
COMMENTED
Rheumatoid Arthritis
Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
Arthritis Res Ther.
Strand V, Gossec L, Proudfoot CWJ, Chen CI, Reaney M, Guillonneau S, Kimura T, van Adelsberg J, Lin Y, Mangan EK, van Hoogstraten H, Burmester GR
doi: 10.1186/s13075-018-1614-z.
COMMENTED
Rheumatoid Arthritis
Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
doi: 10.1186/s13075-019-2059-8.
Rheumatoid Arthritis
Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
Clin Rheumatol.
van der Heijde D, Durez P, Schett G, Naredo E, Østergaard M, Meszaros G, De Leonardis F, de la Torre I, López-Romero P, Schlichting D, Nantz E, Fleischmann R
doi: 10.1007/s10067-018-4221-0.
Rheumatoid Arthritis
Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes
J Rheumatol.
Bechman K, Tweehuysen L, Garrood T, Scott DL, Cope AP, Galloway JB, Ma MHY
doi: 10.3899/jrheum.171375.
Rheumatoid Arthritis
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
Ann Rheum Dis.
Keystone EC, Taylor PC, Tanaka Y, Gaich C, DeLozier AM, Dudek A, Zamora JV, Cobos JAC, Rooney T, Bono S, Arora V, Linetzky B, Weinblatt ME
doi: 10.1136/
Rheumatoid Arthritis
Analysis of effectiveness, safety and optimization of tocilizumab in a cohort of patients with rheumatoid arthritis in clinical practice
Reumatol Clin.
Mena-Vázquez N, Manrique-Arija S, Rojas-Giménez M, Ureña-Garnica I, Jiménez-Núñez FG, Fernández-Nebro A
doi: 10.1016/